DOR BioPharma, Inc. Announces Positive Interim Results from Phase I Clinical Trial of RiVax(TM), its Ricin Toxin Vaccine

21-Jun-2005

DOR BioPharma, Inc. announced positive interim results from its ongoing Phase I clinical trial of RiVaxTM, its vaccine against ricin toxin. The Phase I clinical trial of RiVaxTM represents the first ricin toxin vaccine ever to be clinically tested in humans and is being conducted by DOR's academic partner, a group led by Dr. Ellen Vitetta at the University of Texas Southwestern Medical Center at Dallas. In the rising dose, open label trial, three cohorts of 5 normal volunteers each have been dosed three times with 10, 33 and 100 micrograms. These interim data are from the first two lower dose cohorts of volunteers. Early results demonstrate that the vaccine is safe and immunogenic after immunization with three monthly injections of vaccine, with volunteers developing antibodies. This is the first indication that a ricin toxin vaccine elicits immune responses and predicts that humans can be protected against ricin exposure. Antibody data from all three cohorts is expected in the next several months.

RiVax(TM) is a form of ricin that consists of a fragment of the toxin that has been proven in pre-clinical studies to be non-toxic but retains the capacity to elicit protective immunity.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances